ASCO 2026 highlighted a shift toward precision-driven oncology R&D, where biomarkers, ctDNA, and integrated strategies guide ...
Hengrui and Kailera have been vocal about positioning the drug as being capable of improving the clinical profile of existing ...
Amid an ongoing expansion of China’s volume-based procurement (VBP) scheme to lower drug costs, the Chinese government has ...
Merck’s MRK stock is trading above its 50-day and 200-day simple moving averages (SMAs), a positive technical signal that ...
Her story is one of a growing number of Australians, New Zealanders, Europeans, and Americans who are travelling to China for ...
Once rapidly fatal, neglected, and orphan diseases without approved therapeutic options, systemic amyloidoses are now highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results